Bayer Vietnam Partners with Hanoi Stroke Association and the University of Oxford to Enhance Scientific Research Capacity and Stroke Management in Vietnam

Hanoi, 15 July 2024 - Bayer Vietnam, the Hanoi Stroke Association (HNSA), and the University of Oxford announce a new collaboration to enhance stroke management and the quality of scientific research in Vietnam. The MOU signing ceremony, held at the Stroke Center, Bach Mai Hospital, and witnessed by leaders from all partner organizations, marks a significant milestone in the joint effort to improve patient care and outcomes.

Recognising the critical role of ongoing research and scientific data analysis in the treatment of atrial fibrillation and stroke, the three parties are committed to the shared goal of strengthening research capacity and fostering the development and publication of clinical data within the medical community in Vietnam. By addressing data gaps, this collective effort supports better clinical decision-making and the optimisation of patient care.

Under the MOU, a comprehensive program titled "Improving the Quality of Scientific Research and Stroke Management, period 2024-2025" will be developed, encompassing various key areas of scientific research and publication activities. Specific program will be further discussed and agreed upon by the parties, considering the criteria and capacity of each organization.

Furthermore, the partnership seeks to establish and nurture professional collaboration with international organizations to elevate the quality of stroke research in Vietnam. By combining local expertise and data with technical guidance from counterparts at leading medical institutions overseas, multi-national projects are expected to generate more robust insights applicable worldwide, strengthening the global contribution of Vietnamese stroke specialists while expediting adoption of evidence-based best practices in the country.

According to Mr Ingo Brandenburg, Managing Director of Bayer Vietnam, the company will actively collaborate with medical experts in developing training programmes for healthcare professionals and the community. Leveraging its scientific expertise, Bayer will provide input to enhance the quality of training and education programmes, facilitate knowledge updates, and further contribute to the overall objectives of the partnership, in consultation with the Hanoi Stroke Association, the University of Oxford, and the respective experts involved.

“This solidarity between leading organisations represents a significant step for stroke care and research in Vietnam. By combining strengths, we hope to empower healthcare professionals and tangibly enhance patient well-being. This is aligned with our vision of Health for all,” Mr Ingo Brandenburg emphasised at the ceremony.

Dr Tran Cong Minh, Researcher at the University of Oxford, shared, “Today’s ceremony represents a collaborative effort to enhance scientific research and stroke management. Partnering with the Hanoi Stroke Association and Bayer Vietnam has reaffirmed our commitment to improving treatment quality through developing research, training medical programmes, and updating the latest clinical data.”

With a sustained, multi-pronged approach over the coming years, this alliance is well-positioned to make a truly meaningful and lasting impact—elevating standards of treatment, research, and patient outcomes to international levels. Ultimately, through these collective efforts, more Vietnamese families will gain access to quality stroke management that improves lives.

About Hanoi Stroke Association

Hanoi Stroke Association is a socio-professional organisation of Vietnamese citizens based in Hanoi, with nationwide impact. The Association operates with the mission of improving professional qualifications and standardising techniques in the fields of research, training, diagnosis, and treatment of stroke and related areas.

About the University of Oxford

The University of Oxford was ranked first by Times Higher Education and second among global universities in the QS World University Rankings. The foundation of this success is built on innovative, ground-breaking scientific achievements.

The University of Oxford is renowned for excellence in scientific research and is home to many outstanding and talented individuals from around the globe. We continuously strive to enhance the lives of millions of people and solve important problems facing the world through our broad partner network. Our scale and multidisciplinary research enable us to bring new ideas and innovations with unique solutions.

Through its research commercialisation arm, Oxford University Innovation, Oxford is the leading university in the United Kingdom in terms of patent applications as well as the number of associated commercial companies, with 200 companies established since 1988. More than one-third of these businesses were created in the past three years. The university plays a major role in bringing prosperity to Oxfordshire and the United Kingdom, contributing £15.7 billion to the British economy in 2018/19 and creating over 28,000 full-time jobs.

The Nuffield Department of Clinical Neurosciences has developed a long-standing research and training programme known for its strong reputation both locally and internationally. The department consists of five divisions: Wolfson Centre for Prevention of Stroke and Dementia, Division of Clinical Neurology, Nuffield Division of Anaesthetics, Nuffield Laboratory of Ophthalmology, and Wellcome Centre for Integrative Neuroimaging. Located at John Radcliffe Hospital, the Nuffield Department of Clinical Neurosciences has cultivated a comprehensive environment where research activities, education, training, and clinical care are closely connected. This allows the department to develop new approaches and methods for the discovery, diagnosis, and treatment of brain diseases.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to address the major challenges presented by a growing and ageing global population. Bayer is committed to driving sustainable development and generating a positive impact through its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements 

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties, and other factors could lead to material differences between the actual future results, financial situation, development, or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.